Synthesis and AMPA receptor antagonistic activity of a novel class of quinoxalinecarboxylic acid with a substituted phenyl group at the C-7 position

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 20, 2003, Pages 3521-3525

  Takano, Yasuo ^a   Shiga, Futoshi ^a   Asano, Jun ^a   Ando, Naoki ^a   Uchiki, Hideharu ^a   Anraku, Tsuyosi ^a  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 (1 IMIDAZOLYL) 7 NITRO 2,3 QUINOXALINEDIONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; CARBOXYLIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; QUINOXALINE DERIVATIVE; [1,2,3,4 TETRAHYDRO 7 (1H IMIDAZOL 1 YL) 6 NITRO 2,3 DIOXO 1 QUINOXALINYL]ACETIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; NEUROPROTECTION; NONHUMAN; RAT;

EID: 0141851403     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00740-6     Document Type: Article

References (22)

1. Satkowski M., Attwell D. Trends Neurosci. 17:1994;359.
2. Gorter J.A., Petrozzino J.J., Aronica E., Rosenbaum D.M., Opits T., Bennet M.V.L., Connor J.A., Zukin R.S. J. Neurosci. 17:1997;6179.
3. Advokat C., Pellegrin A.I. Neurosci. Biobehav. Rev. 16:1992;13 Wouter K., James H.W., Gail D.W. J. Pharmacol. Exp. Ther. 245:1958;969.
4. Advokat C., Pellegrin A.I. Neurosci. Biobehav. Rev. 16:1992;13 Wouter K., James H.W., Gail D.W. J. Pharmacol. Exp. Ther. 245:1958;969.
5. Sheardown M.J., Nielsen E.O., Hansen A.J., Jacobsen P., Honore T. Science. 247:1990;571 Judge M.E., Sheardown M.J., Jacobsen P., Honore T. Neurosci. Lett. 133:1991;291.
6. Sheardown M.J., Nielsen E.O., Hansen A.J., Jacobsen P., Honore T. Science. 247:1990;571 Judge M.E., Sheardown M.J., Jacobsen P., Honore T. Neurosci. Lett. 133:1991;291.
7. Ohmori J., Sakamoto S., Kubota H., Shimizu-Sasamata M., Okada M., Kawasaki S., Hidaka K., Togami J., Furuya T., Murase K. J. Med. Chem. 37:1994;467.
8. (a) Shishikura, J.; Tsukamoto, S.; Inami, H.; Fujii, M.; Okada, M.; Sasamata, M.; Sakamoto, S. WO 9610023; Chem. Abstr. 1996, 125, 114689.
9. (b) Kawasaki-Yatsugi S., Yatsugi S., Takahashi M., Toya T., Ichiki C., Shimizu-Sasamata M., Yamaguchi T., Minematsu K. Brain. Res. 793:1998;39.
10. Xue D., Huang Z.-G., Barnes K., Lesiuk H.J., Smith K.E., Buchan A.M. J. Cereb. Blood Flow Metab. 14:1994;251.
11. (a) Bigge C.F., Boxer P.A., Ortwine D.F. Curr. Pharm. Des. 2:1996;397
12. (b) Bigge C.F., Nikam S.S. Exp. Opin. Ther. Pat. 7:1997;1099.
13. Jeanne, H. S.; Graham, J.; Joseph, L. L.; Charles, M. T.; Michael, N. P. WO 92 11,245; Chem. Abstr. 1992, 118, 101927t.
14. This compound, 3-hydroxymethyl-4-pyridone, was synthesized from reduction by sodium borohydride of 3-formyl-4-hydroxypyridine, which was prepared by lithiation of 4-chloropyridine followed by treatment of N,N-dimethylformamide, and hydroxylation with NaOH solution.
15. Bloemhoff W., Kerling K.E.T. Recl. Trav. Chim. Pays-Bas. 89:1970;1181.
16. (a) Johansen T.H., Drejer D., Watjen F., Nielsen E.O. Eur. J. Pharmacol. 246:1993;195
17. (b) Neil L.H., Michael A.S. Br. J. Pharmacol. 84:1985;381.
18. Murphy D.E., Hutchison A.J., Hurt S.D., Williams M., Sills M.A. Br. J. Pharmacol. 95:1988;932.
19. Tamura A., Graham D.I., McCulloch J., Teasdale G.M. J. Cereb. Blood Flow Metab. 1:1981;53.
20. 14 brains were removed and sliced into five coronal (2 mm thick) sections with the use of a rat brain matrix (a manual slicer). Slices were placed in 2% (w/v) triphenyltetrazolium chloride (TTC) solution, and then in 10% (v/v) phosphate-buffered formalin. Tissue damage (areas not stained with TTC) was scored on a four-point scale (see Fig. 2.
21. Solubility test: The solubility of test compounds was determined in 0.1 M phosphate buffer (pH 7.4) at room temperature. After centrifugation, the concentrations in the supernatant were assayed by HPLC. The results at pH 7.4 were as follows: compounds 1 and 2, <1 mg/mL; compound 3, >5 mg/mL; compound 15l, 4.86 mg/mL: Takeru, H.; Fong-Mei, L. S.; Toshikiro, K.; Ryttingj, J. H. J. Pharm. Sci. 1979, 68, 1267.
22. 2O: C, 47.55; H, 3.42; N, 15.65. Found: C, 47.46; H, 3.33; N, 15.65.